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Toll-like receptors (TLRs) play a key role in the activation of innate immune cells, in 
which their engagement leads to production of cytokines and co-stimulatory mol-
ecules. TLRs signaling requires recruitment of toll/IL-1R (TIR) domain-containing 
adaptors, such as MyD88 and/or TRIF, and leads to activation of several transcription 
factors, such as NF-κB, the AP1 complex, and various members of the interferon 
regulatory factor (IRF) family, which in turn results in triggering of several cellular 
functions associated with these receptors. A role for Src family kinases (SFKs) in this 
signaling pathway has also been established. Our work and that of others have shown 
that this type of kinases is activated following engagement of several TLRs, and that 
this event is essential for the initiation of specific downstream cellular response. In 
particular, we have previously demonstrated that activation of SFKs is required for 
balanced production of pro-inflammatory cytokines by monocyte-derived dendritic 
cells after stimulation with R848, an agonist of human TLRs 7/8. We also showed that 
TLR7/8 triggering leads to an increase in interferon regulatory factor 1 (IRF-1) protein 
levels and that this effect is abolished by inhibition of SFKs, suggesting a critical role 
of these kinases in IRF-1 regulation. In this study, we first confirmed the key role of 
SFKs in TLR7/8 signaling for cytokine production and accumulation of IRF-1 protein 
in monocytes and in B lymphocytes, two other type of antigen-presenting cells. Then, 
we demonstrate that TLR7 triggering leads to an increase of K63-linked ubiquitination 
of IRF-1, which is prevented by SFKs inhibition, suggesting a key role of these kinases 
in posttranslational regulation of IRF-1 in the immune cells. In order to understand the 
mechanism that links SFKs activation to IRF-1 K63-linked ubiquitination, we examined 
SFKs and IRF-1 possible interactors and proved that activation of SFKs is necessary 
for their interaction with TNFR-associated factor 6 (TRAF6) and promotes the recruit-
ment of both cIAP2 and IRF-1 by TRAF6. Collectively, our data demonstrate that 
TLR7/8 engagement leads to the formation of a complex that allows the interaction of 
cIAP2 and IRF-1 resulting in IRF-1 K63-linked ubiquitination, and that active SFKs are 
required for this process.
Keywords: toll-like receptor, innate immunity, interferon regulatory factor 1, ubiquitination, TnF receptor 
associated factor 6, src family kinases
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inTrODUcTiOn
The innate immune system represents the first defense mecha- 
nism engaged by the host organism against pathogen infections 
and is also required to activate adaptive immune responses. 
A central role in coupling innate and adaptive immunity is played 
by toll-like receptors (TLRs) (1–4). Following recognition of 
highly conserved pathogen-associated molecular patterns (5, 6), 
TLRs activate a signaling cascade that in turn leads to the pro-
duction of pro-inflammatory cytokines and co-stimulatory mol-
ecules, which are required for the response to pathogens (4, 7). 
Due to their critical role in the activation of the innate immune 
response TLRs are preferential targets of new vaccine adjuvants 
based on small molecules (8).
TLR7 and TLR8 belong to a subfamily of endosomal recep-
tors that recognize single-stranded RNAs from viruses as well 
as endogenous nucleic acids released in the context of patho- 
genic events (9, 10). TLR7 has been shown to be a good target 
for a recently described vaccine adjuvant (11, 12). Engagement 
of these two TLRs by appropriate agonists triggers an intracel-
lular signaling pathway that involves recruitment of the adaptor 
protein Myeloid differentiation primary response 88 (MyD88), 
which in turn binds interleukin 1 (IL-1) receptor-associated ki- 
nase family of protein kinases. Activation of these serine/threo-
nine kinases leads, through TNFR-associated factor 6 (TRAF6), 
to activation of MAP kinases and nuclear translocation of the 
transcription factor NF-κB, which are required for induction of 
inflammatory cytokines. Members of the interferon regulatory 
factor (IRF) family of transcription factors are also induced by 
intracellular TLRs such as TLR7 and TLR8, resulting in trigger-
ing of other cellular functions associated with these receptors. 
TLR7 stimulation in plasmacytoid DC activates IRF-7 that in 
turn leads to IFNα production (13), while in conventional DC, 
TLR7 engagement is associated to interferon regulatory factor 
(IRF-1) induction, which in these cells controls cytokine gene 
expression (14–16). Src family kinases (SFKs) were also shown to 
participate in TLRs signaling (17–24). Activity of these kinases is 
finely regulated by a balance of phosphorylation and dephospho-
rylation events (25). Phosphorylation of their carboxyl-terminal 
tyrosine residue (Tyr-530 in human c-Src), mainly by C-terminal 
Src kinase, leads to an intramolecular interaction of this phos-
phorylated residue with the Src homology (SH) 2 domain, result-
ing in an enzymatically inactive closed conformation of SFKs. 
Dephosphorylation of the carboxyl-terminal tyrosine residue 
by several phosphatases or displacement of the intramolecular 
SH2 domain by another protein with a higher affinity SH2 do- 
main opens up the kinase domain, which becomes catalytically 
active. This event allows intermolecular autophosphorylation of 
a tyrosine residue in the activation loop (Tyr-419 in human c-Src), 
which locks the catalytic pocket into an open conformation and 
is required for maximum activation of these kinases. PP2 is a 
small molecule inhibitor of SFKs, which binds specifically these 
kinases, preventing the auto-phosphorylation in the activation 
loop that is necessary for the full activation of SFKs (26). We pre-
viously demonstrated that pharmacological inhibition of SFKs 
with PP2 in human monocyte-derived dendritic cells (MoDCs) 
impaired TLR7/8-mediated release of several pro-inflammatory 
cytokines by interfering with the accumulation of IRF-1, thus sug-
gesting an involvement of SFKs in IRF-1 regulation and TLR7/8 
signaling (16).
Interferon regulatory factor 1 is the prototype member of a 
family of nine transcription factors (27, 28) and is expressed in 
a variety of cells in which plays a crucial role in promoting the 
expression of type I IFN genes following viral infection (29–31). 
Similar to other transcription factors, IRF-1 is tightly regulated 
at both transcriptional and posttranslational levels (32–35). In 
particular, IRF-1 can undergo K48-ubiquitination to be degraded 
via the proteasome pathway (36), or K63-ubiquitination through 
the recruitment of TRAF6 and cIAP2 to become activated follow-
ing IL-1R stimulation (37).
Here, we show that a similar signaling pathway involving 
TLRs and SFKs controls IRF-1 expression and cytokine produc-
tion in two other important classes of antigen-presenting cells, 
namely monocytes and B-lymphocytes, which are key target for 
vaccine adjuvants. Moreover, we provide evidence that SFKs 
control the TLR7/8-dependent release of pro-inflammatory 
cytokines by monocytes and B-lymphocytes by promoting 
K63-linked ubiquitination of IRF-1. Finally, we demonstrate a 
crucial role of SFKs in binding and activating the ubiquitin ligase 
TRAF6 and that its inhibition impairs the formation of a com- 
plex with cIAP2 and IRF-1 that is a crucial step for IRF-1 K63-
linked ubiquitination.
MaTerials anD MeThODs
cell cultures
Human embryonic kidney cells stably expressing human TLR7 
(hTLR7-HEK293 cells) were cultured in DMEM containing 
4.5 g/ml glucose, supplemented with 10% heat inactivated FBS, 
100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM glutamine, 
5 µg/ml puromycin, 5 µg/ml blasticidin, and 2 mM glutamine. 
Human monocytic leukemia cell line THP-1 were cultured in 
RPMI 1640 containing 2.5 g/l glucose, supplemented with 10% 
heat inactivated FBS, 10 mM HEPES, 10 mM Sodium Pyruvate, 
100 U/ml penicillin, and 100 µg/ml streptomycin.
PBMCs were isolated from buffy coats of healthy donors using 
Ficoll gradient. Human primary B cells were purified by nega-
tive selection using the RosetteSep B-cell enrichment Cocktail 
(StemCell Technologies) followed by density gradient cen-
trifugation on Lympholite (Cedarlane Laboratories) as previously 
described (38). Monocytes were isolated from purified human 
PBMC using anti-CD14 magnetic beads (Miltenyi Biotec). 
Informed consent was obtained according to the Declaration of 
Helsinki.
Epstein–Barr virus (EBV)-immortalized B cell line and human 
primary B  cells were cultured in RPMI 1640 (Sigma-Aldrich, 
The Woodlands, TX, USA) supplemented with 7.5% bovine calf 
serum at 37°C in a humidified atmosphere with 5% CO2.
cell Treatment and cytokine Detection
Cells were treated with 20 µM PP2 (Sigma-Aldrich) or DMSO 
for 30  min then stimulated with R848 (10  µM) (Invivogen) 
overnight. Supernatants were collected and the amount of 
inflammatory cytokines was measured using Mesoscale Assay 
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Human-Pro-inflammatory 7-spot (Meso Scale Discovery), fol-
lowing the manufacturer’s instructions.
cell Transfection
hTLR7-HEK293 cells were seeded in 100 mm diameter culture 
dishes (3 × 106 cells/dish) and after 24 h were transfected using 
Lipofectamine 2000 (Invitrogen) with an expression plasmid 
encoding hemagglutinin (HA)-tagged K48-only or K63-only 
ubiquitin (kindly provided by Dr. Jonathan Ashwell, NCI, NIH, 
Bethesda, MD, USA). Four days post-transfection cells were 
treated as described above. THP-1 cells were seeded in 100 mm 
diameter culture dishes (6  ×  106  cells/dish) and immediately 
transfected by Lipofectamine 2000 (Invitrogen) with an expres-
sion plasmid encoding HA-tagged Ubiquitin. After 24  h, cells 
were treated as described above.
immunoprecipitation and  
immunoblot analysis
Cells were treated with 20 µM PP2 at concentration or DMSO 
for 30 min prior to incubation with R848 (10 µM) for 2 h, then 
lysed with a buffer containing 150 mM NaCl, 20 mM Tris–HCl, 
Triton X-100 1%, 1 µg/ml pepstatin A, 1 µg/ml leupeptin, 1 µg/ml 
aproteinin, 200  µg/ml sodium orthovanadate, 1  mM phenyl-
methylsulfonyl fluoride, and 1 mg/ml of N-ethylmaleimide, for 
5 min on ice. Lysates were centrifuged for 20 min at 21,000 × g 
at 4°C. Protein concentration was measured using the Bradford 
assay (Sigma-Aldrich). Proteins were separated by 10% SDS-
PAGE electrophoresis using the NuPage Gel System, according 
to the manufacturer’s instructions and transferred to nitrocel-
lulose membranes for Western blot analysis. After blocking with 
PBS containing 0.05% Tween 20 (PBST) and 5% BSA (Sigma-
Aldrich), proteins were detected with specific antibodies.
For immunoblot and immunoprecipitation analysis, we used 
the following antibodies: anti-IRF-1 (cat# 8478 Cell Signaling 
for immunoblot and cat# sc-497 Santa Cruz Biotechnology for 
immunoprecipitation); anti-TRAF6 (cat# 8028 Cell Signaling); 
anti-Src (cat# 2108 Cell Signaling); anti-p-SFKs (Tyr416) (2101 
Cell Signaling); anti-p-Tyrosine (cat# 8954 Cell Signaling); anti-
HA (cat# 2367 Cell Signaling); anti-cIAP2 (cat# ab32059 Abcam), 
anti-β-actin (cat# ab8227 Abcam); and HRP-conjugated second-
ary antibodies (DAKO).
The same filters were stripped and re-probed with an anti-
actin antibody (cat#mab1501 Millipore) for loading control. 
Immunoblots were captured for densitometry using ImageJ 
software, and each signal was normalized to its respective protein 
signal on the same blot.
For immunoprecipitations, cell lysates were incubated over-
night at 4°C with the primary antibody crosslinked with the BS3 
reagent to Dynabeads® Protein G Immunoprecipitation Kit (Life 
Technologies). Crosslinking avoid the co-elution of IgGs with 
the targed antigen. Immunoprecipitated complexes were eluted 
and analyzed by Western blot. To analyze TRAF6 tyrosine phos-
phorylation, lysates were immunoprecipitated with anti-TRAF6 
antibody. The immune complexes immobilized on Dynabeads 
were then resuspended in 2% SDS and heat-treated (90°C for 
5  min) to disrupt the interaction between TRAF6 and SFKs. 
The protein mixture was diluted in PBS to reduce the SDS to a 
final concentration of 0.01%, and re-immunoprecipitated with 
the same anti-TRAF6 antibodies. The re-immunoprecipitated 
samples were eluted and analyzed by western blot. To control 
for efficiency of immunoprecipitation and protein loading and 
transfer, the blots were stripped and re-probed  with the antibody 
used for immunoprecipitation. Immunoblots were captured for 
quantitative densitometry using ImageJ software, and each signal 
was normalized to its respective protein signal on the same blot.
rna Purification and Quantitative rT-Pcr
Total RNA was extracted from THP-1, human B  cells and 
HEK-293 using the RNeasy Plus Mini Kit (Qiagen) and retro-
transcribed using the iScript™ cDNA Synthesis Kit (Bio-Rad, 
Hercules, CA, USA). Three independent reverse transcription 
reactions were performed on each sample. Real-time quantita-
tive PCR (qRT-PCR) was performed in triplicate on each cDNA 
in 96-well optical PCR plates (Sarstedt, Nümbrecht, Germany) 
using SSo Fast EvaGreenR SuperMix (Bio-Rad) and a CFX96 
Real-Time system (Bio-Rad). Results were processed and 
analyzed using CFX Manager Version 1.5 software (Bio-Rad). 
Transcript levels were normalized to HPRT1 used as housekeep-
ing control for all the reactions. The primers sequences are as 
follow: HPRT1 forward 5’-AGATGGTCAAGGTCGAAG-3’ and 
reverse 5’-GTATTCATTATAGTCAAGGGCATAT-3’; IRF-1 for- 
ward 5’-CGTGGGACATCAACAAGGA-3’ and reverse 5’-GTG 
GAAGCATCCGGTACACT-3’.
statistical analysis
Mean values, SDs and Student’s t-test (unpaired) were calcula-
ted using Microsoft Excel Version 14.0.0 software (Microsoft) 
(Redmont, WA, USA). A P <  0.05 was considered statistically 
significant.
resUlTs
activation of sFKs is required for 
inflammatory cytokine Production in both 
Monocyte-like cells and Primary B cells
We have previously demonstrated that SFKs activity is required 
for the release of pro-inflammatory cytokines by human Mo- 
DCs stimulated with the imidazoquinoline compound R848 
(Resiquimod), an agonist for human TLR7 and TLR8 (16). To un- 
derstand whether this mechanism is shared by other immune 
cells, which are also targets for a TLR7/8 agonist vaccine adjuvant, 
we extended our analysis to monocytes and B-lymphocytes.
Human monocytic THP-1 cells and human primary monocytes 
and B cells were stimulated for 16 h with R848 in the absence or in 
the presence of the SFKs-specific inhibitor PP2 and cell superna-
tants were collected and analyzed using the multiplex Meso Scale 
Discovery immunoassay to measure the levels of 7 inflammatory 
cytokines in the culture supernatants. As shown in Figure  1, 
we observed a strong induction in the release of 4 of the 7 pro-
inflammatory cytokines analyzed, specifically TNFα, IL-6, IL-8, 
and IL-1β in THP-1 cells (panel A) and in primary B cell (panel 
B), while in response to R848 only TNFα, IL-6 and IL-1β were 
released by human primary monocytes (panel C). However, in 
FigUre 1 | Src family kinases inhibition results in decrease of pro-inflammatory cytokine production in response to TLR7/8 stimulation in monocytes and B cells. 
THP-1 (a) and primary human B cells (B) were pretreated with PP2 (20 µM) or DMSO alone for 30 min and stimulated with R848 (10 µM) for 16 h. Monocytes  
(c,D) were pretreated with PP2 (20 µM) or DMSO alone for 30 min and stimulated with R848 (1 µM) for 16 h. Cytokine levels in the supernatants were quantified  
by Meso Scale Discovery immunoassay. Cells treated with vehicle only (DMSO) were used as control (Ctr). (a,B) Values represent the mean ± SD of cytokine 
concentration (picogram per milliliter) in the culture supernatants (n ≥ 3), ***P < 0.001, **P < 0.01, *P < 0.05. Results are representative at least of three independent 
experiments. (c,B) The histograms show the mean (from duplicate samples) ± SD of cytokine concentration (pg/ml) in the culture supernatants from two different 
donors respectively in panels (c,D) and are representative of four experiments performed on monocytes from four different donors.
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FigUre 2 | Src family kinases are required for interferon regulatory factor 1 (IRF-1) protein accumulation in response to TLR7/8 stimulation in monocytes and 
B cells. (a,c) Immunoblot analysis of IRF-1 and p-SFKs in THP-1 (a) and primary B cells (c) pretreated with PP2 (20 µM) or DMSO alone and stimulated with  
R848 (10 µM) for 2 h. After stripping, filters were re-probed with an antibody against actin as loading control. Results are representative at least of three independent 
experiments. The histograms on the right of the blot show the results of the densitometric analysis on three independent experiments. Each signal was normalized 
to its respective actin signal on the same blot and expressed as fold induction (mean ± SD) compared to untreated sample. (B,D) qRT-PCR analysis of lRF-1 mRNA 
in THP-1 (B) and human B cells (D) pretreated with PP2 (20 µM) or DMSO alone and stimulated with R848 (10 µM) for 2 h. The relative abundance of the gene 
transcripts was determined on triplicate samples from at least three independent experiments using the ΔΔCt method and is expressed as the normalized fold 
expression (mean ± SD) compared to untreated sample. **P < 0.01, *P < 0.05.
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all cases, cytokine production was largely reversed when SFKs 
were inhibited by PP2 pretreatment.
Hence, SFKs activation is a critical event for cytokine produc-
tion also in human monocytes and B cells.
sFKs Play a Key role in the accumulation 
of irF-1 in ThP-1 and B cells
Analysis of the signaling pathways triggered in MoDCs by R848 
identified IRF-1 as the main effector responsible for the transcrip-
tion of pro-inflammatory genes. Activation of this transcription 
factor was directly correlated with the activation of SFKs (16).
To evaluate whether IRF-1 was similarly involved in the re- 
lease of pro-inflammatory cytokines in THP-1 and B  cells, we 
analyzed its expression and activation in these cells after R848 
stimulation. As shown in Figures 2A,C, stimulation of THP-1 cells 
or primary B cells with R848 for 2 h resulted in IRF-1 accumula- 
tion (upper western blot and left histogram in Figures  2A,C), 
which directly correlated with an increase in the auto-phospho-
rylation of SFKs on the activator Tyr residue (Y419 in c-Src) 
(middle western blot and right histogram in Figures 2A,C), that 
indicates activation of this type of kinases. These effects were all 
inhibited by pretreatment with PP2, confirming the importance of 
SFKs activation in the up-regulation of this transcription factor.
We next measured IRF-1 mRNA levels by qRT-PCR in cells 
treated as described above to assess whether the changes in IRF-1 
expression were dependent on transcriptional regulation of the 
respective gene by SFKs. The level of IRF1 mRNA was increased 
following stimulation with R848 in THP1 cells (Figure  2B) 
and primary B  cells (Figure  2D). Interestingly, no decrease in 
the transcript was observed in either cell types when cells were 
pre-treated with PP2, suggesting that, as previously shown for 
MoDCs, in these cells SFKs regulate IRF-1 expression posttran-
scriptionally The analysis was also extended to EBV-immortalized 
primary human B lymphocytes (EBV-B). Interestingly, no 
changes in the mRNA levels were detected in these cells treated 
with R848, either in the presence or absence of PP2 (Figure S1A 
in Supplementary Material). Nevertheless, similar to THP-1 and 
primary B cells, we observed an accumulation of IRF-1 protein 
in R848-treated EBV-B cells that was blocked by PP2 (Figure S1B 
in Supplementary Material).
Collectively, these results support the hypothesis that 
posttranslational modifications, in addition to transcription 
activa tion, lead to IRF-1 accumulation as a consequence of SFKs 
activation.
sFKs activation is essential for  
K63-linked Ubiquitination of irF-1
To elucidate the mechanism responsible for IRF-1 downregula-
tion in PP2 treated cells, we asked whether SFKs might prevent 
IRF-1 degradation by promoting posttranslational modifications 
in the protein. In fact, it has been reported that IRF-1 can undergo 
several posttranslational modifications, including sumoylation 
FigUre 3 | Src family kinases activation is essential for interferon regulatory 
factor 1 (IRF-1) K63-linked ubiquitination. (a) Immunoblot analysis of IRF-1 
and pSFKs in hTLR7-HEK293 cells pretreated or not with PP2 (20 µM) for 
30 min and stimulated with R848 (10 µM) for 2 h. After stripping, membranes 
were blotted with anti-actin antibody as loading control. The histograms on 
the right of the blots show the results of the densitometric analysis on three 
independent experiments. Each signal was normalized to its respective actin 
signal on the same blot and expressed as fold induction (mean ± SD) 
compared to untreated sample. (B,c) hTLR7-HEK293 cells transiently 
transfected with plasmids coding for hemagglutinin (HA)-tagged K63-only  
(B) or K48-only ubiquitin mutants (c) were pretreated or not with PP2 
(20 µM) for 30 min and stimulated for 2 h with R848 (10 µM). Total cell  
lysates were immunoprecipitated using an anti-IRF-1 antibody, separated  
by SDS-PAGE, and immunoblotted using anti-HA antibody for ubiquitin 
detection. Membranes were stripped and re-probed with an anti-IRF-1 
antibody as control (bottom panels). The histograms on the right of the blots 
show the results of the densitometric analysis on three independent 
experiments. Each signal was normalized to the signal of the protein used  
for the pull-down and expressed as fold induction (mean ± SD) compared to 
untreated sample. ***P < 0.001, **P < 0.01, *P < 0.05.
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and ubiquitination (35). K48-linked ubiquitination of IRF-1 has 
been shown to target the protein to the proteasome for degrada-
tion (36) whereas K63-linked ubiquitination is essential for IRF-1 
activity (37).
To investigate whether SFKs modulate IRF-1 ubiquitination 
upon TLR7/8 engagement, we used HEK293 cells stably express-
ing human TLR7 (hTLR7-HEK293) as a specific cell model for 
studying the TLR7 signaling cascade. As observed in immune 
cells, stimulation of these cells with R848 led to an accumulation 
of IRF-1 that was reversed by PP2 treatment that also resulted in 
the inhibition of SFKs phosphorylation (Figure 3A). To analyze 
IRF-1 ubitiquination, hTLR7-HEK293 cells were transiently 
transfected with plasmids coding for HA-tagged K63-only or 
HA-tagged K48-only ubiquitin mutants and cell lysates were 
subjected to immunoprecipitation using an anti-IRF-1 antibody. 
As shown in Figure 3B, R848 stimulation resulted in an increase 
in the level of K63-linked ubiquitination of IRF-1, which was 
drastically reduced by pretreatment with PP2. Conversely, K48-
linked ubiquitinated IRF-1 accumulated when cells were preincu-
bated with PP2 (Figure 3C). It should be noted that, to normalize 
the levels of immunoprecipitated IRF-1 and thus avoiding 
that differences in the levels of ubiquitination could depend on 
the different levels of IRF-1 in the immunoprecipitates, a limiting 
amount of antibody was used to perform the immunoprecipita-
tion. This resulted in similar levels of immunoprecipitated IRF-1 
in all samples (lower blots in Figures  3B,C). Similar results 
were observed in THP-1 cells transiently transfected with 
HA-tagged K63-only or K48-only ubiquitin mutants (Figure S2 
in Supplementary Material). To confirm the specificity of these 
results, we immunoprecipitated the lysates of hTLR7-HEK293 
cells transiently transfected with HA-tagged K63-only or HA- 
tagged K48-only ubiquitin mutants with an anti-HA antibody 
and then we processed the immunoprecipitates for IRF-1 immu-
noblotting (Figure S3 in Supplementary Material). Also in this 
case TLR7 engagement increased the levels of IRF-1 in the K63 
ubiquitinated pool, which were inhibited by PP2 treatment, 
while Src kinase inhibition resulted in an expansion of the K48 
ubiquitinated form. Taken together, these findings indicate that 
SFKs play a crucial role in the regulation of the balance between 
accumulation and degradation of IRF-1.
sFKs activation regulates the interaction 
of irF-1 with ciaP2 and TraF6
TNFR-associated factor 6 is an ubiquitin ligase that catalyzes 
the K63-linked ubiquitination of several signaling molecules 
(39–42). Of note, it has been previously reported that TRAF6 
recruits the E3 ligase cIAP2 and IRF-1 in response to IL-1, 
forming a complex that allows K63-linked ubiquitination of 
IRF-1 by cIAP2 (37). Moreover, Liu A. et al. have demonstrated 
a functional association of SFKs and TRAF6 during TLR4 
signaling (43). To establish whether TRAF6 participates in SFKs-
dependent IRF-1 regulation following TLR7/8 activation, lysates 
from hTLR7-HEK293 cells stimulated with R848 in the presence 
or absence of PP2 were subjected to co-immunoprecipitation 
experiments to assess protein–protein interactions. Analysis of 
TRAF6-specific immunoprecipitates showed that this protein 
forms a complex with IRF-1, Src, and cIAP2 at steady state as 
well as following R848 stimulation. However, treatment with PP2 
impaired the binding of TRAF6 with Src and cIAP2 (Figure 4A), 
thus showing that activation of SFKs is required for a stable 
interaction within this complex. On the other hand, when IRF-1 
FigUre 4 | Inhibition of SFKs impairs the stability of the SFKs-TRAF6-IRF-1-cIAP2 complex (a–c) hTLR7-HEK293 cells were pretreated or not with PP2 (20 µM) 
for 30 min and stimulated for 2 h with R848 (10 µM). Total cell lysates were immunoprecipitated using an anti-TRAF6 (a), anti-interferon regulatory factor 1 (IRF-1) 
(B), or anti-pSFKs (c) antibody, respectively. Co-immunoprecipitated cIAP2, TNFR-associated factor 6 (TRAF6), SFKs, and IRF-1 proteins were detected by 
immunoblot. Histograms on the right side of the blots show the quantification of the relative amount of the pulled-down proteins, calculated on three independent 
experiments. Each signal was normalized to the signal of the protein used for the pull-down and expressed as fold induction (mean ± SD) compared to untreated 
sample. ***P < 0.001, **P < 0.01, *P < 0.05.
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immunoprecipitates were evaluated, only TRAF6 and cIAP2 
were found in the complex, while no Src could be detected either 
before or after TLR7 triggering (Figure  4B). The absence of 
Src in this complex could depend on the fact that the kinase 
directly interacts with TRAF6 and that this interaction is not 
preserved in the anti-IRF-1 immunocomplex. Nevertheless, inhi- 
bition of SFKs by PP2 reduced the amount of associated cIAP2. 
Western blot of Src co-immunoprecipitated molecules confir-
med that the kinase activity is required for TRAF6 binding 
(Figure  4C). Collectively, these results provide evidence that 
under basal conditions TRAF6 is associated with IRF-1, cIAP2, 
and SFKs in a SFKs activity-dependent manner.
Tlr7 engagement leads to src  
K63-linked Ubiquitination and TraF6 
Tyrosine Phosphorylation
Src family kinases have been proposed to promote TRAF6 
phosphorylation that in turn can modify SFKs by adding K63-
linked ubiquitin chains (18, 43). Therefore, we tested whether 
FigUre 5 | TLR7 triggering leads to tyrosine kinase dependent Src K63-linked ubiquitination and TNFR-associated factor 6 (TRAF6) tyrosine phosphorylation. 
hTLR7-HEK293 cells, transiently transfected with plasmids coding for hemagglutinin (HA)-tagged K63-only, were pretreated or not with PP2 (20 µM) for 30 min  
and stimulated for 2 h with R848 (10 µM). (a) Total cell lysates were immunoprecipitated with anti-pSFKs antibody and immunoblotted using anti-HA antibody for 
ubiquitin detection. After stripping, the presence of p-SFKs was assessed by immunoblot analysis using specific antibodies, as control. (B) Total cell lysates were 
immunoprecipitated with anti-TRAF6 and immunoblotted with antibodies against pSFKs, Src, and pTyr. (c) TRAF6-specific immunoprecipitates were eluted with  
2% SDS in order to disrupt the TRAF6-SFKs interaction and after dilution with PBS re-immunoprecipitated with anti-TRAF6 antibody. Results are representative of 
three independent experiments. Histograms on the right side of the blots show the quantification of the pulled-down proteins, calculated at least on two 
independent experiments. Each signal was normalized to the signal of the protein used for the pull-down and expressed as fold induction (mean ± SD)  
compared to untreated sample. ***P < 0.001, **P < 0.01.
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this mechanism might also occur following TLR7/8 activation. 
Total lysates from hTLR7-HEK293 cells transiently transfected 
with plasmids coding for HA-tagged K63-only were subjected to 
immunoprecipitation experiments using an anti-pSFKs antibody 
and then probed by immunoblot with an anti-HA antibody. As 
shown in Figure 5A, we found that R848 stimulation increases 
the level of Src K63-linked ubiquitination, a modification which 
is completely abrogated by inhibition of kinase activity by PP2.
To understand whether in turn, TRAF6 might be regulated 
by SFKs, we immunoprecipitated TRAF6 from hTLR7-HEK293 
cells stimulated with R848 and pretreated or not with PP2. 
Immunoblot analysis with an anti-phospho-tyrosine antibody 
showed that TRAF6 was phosphorylated upon TLR7/8 stimu-
lation in a kinase activity-dependent manner. Blotting this 
immunoprecipitate with an antibody against the activator Tyr 
residue (Y419) of Src confirmed that the active kinase is bound 
to TRAF6 in a kinase activity-dependent manner (Figure 5B). 
To confirm that the tyrosine phosphoprotein detected in TRAF6-
specific immunoprecipitates is indeed TRAF6 and not the co- 
immunoprecipitated and co-migrating tyrosine phosphorylated 
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SFKs, the immunoprecipitated samples were treated with 2% SDS to 
disrupt the TRAF6/pSFKs interaction and re-immunoprecipitated 
using an anti-TRAF6 antibody to purify TRAF6 from all co-
immunoprecipitated proteins. Probing these samples with an 
anti-phospho-tyrosine antibody clearly proved that TRAF6 is 
phosphorylated upon stimulation of TLR7/8, and this event is 
completely blocked by PP2 (Figure 5C) indicating that TRAF6 
phosphorylation is mediated by SFKs. Membranes were stripped 
and re-probed with an anti-pSFKs antibody to verify the absence 
of pSFKs (data not shown).
Collectively, our results provide evidence that following 
TLR7/8 engagement the association between SFKs and TRAF6 
leads to K63-linked ubiquitination of SFKs, which in turn is 
respon sible for the phosphorylation of a tyrosine residue on 
TRAF6. We have shown that these modifications are crucial for 
the formation of a complex between IRF-1, TRAF6 and cIAP2 and 
lead to IRF-1 K63-linked ubiquitination. This posttranslational 
modification has a crucial role in IRF-1 stabilization, which is 
required for the nuclear translocation of the transcription factor 
and the subsequent activation of its target genes.
DiscUssiOn
In this study, we demonstrate that SFKs play an essential role 
in K63-linked ubiquitination of IRF-1 in response to TLR7/8 
triggering. We had previously reported that activation of SFKs 
is required for the release of pro-inflammatory cytokines and 
the accumulation of IRF-1 during TLR7/8 signaling in human 
MoDCs (16). Here, we first show that this mechanism is also 
shared by other cells of the immune system, namely monocytes 
and B-lymphocytes, which are potential target of TLR7/8 agonists 
vaccine adjuvants. Moreover, we demonstrate that Src kinase 
associates with TRAF6 in a complex, which also contains IRF-1 
and cIAP2, and that following TLR7 triggering Src undergoes 
K63-linked ubiquitination and phosphorylates TRAF6. These 
events lead to K63-linked ubiquitination of IRF-1 in the complex, 
which is responsible for the increased levels of this transcription 
factor elicited by TLR7 engagement.
Interferon regulatory factors (IRFs) play a crucial role in the 
connection between innate and adaptive immunity by modu-
lating the activation of immune cells triggered by TLRs (28). 
Indeed, TLR signaling leads to the transcriptional activation 
of a variety of genes as a result of the increase in the levels of 
specific transcription factors (34, 44). To enhance the availabil-
ity of a particular transcription factor, the cells can adopt two 
mechanisms: one is to increase the rate of transcription of the 
gene encoding that particular protein, the other is by promot-
ing its stability and activation. The latter mechanism is mainly 
achieved by specific posttranslational modifications, which may 
prevent protein degradation and increase protein half-life, or 
they may promote or inhibit protein–protein interactions allow-
ing nuclear translocation and binding to the regulatory regions 
of the target genes. This type of mechanisms plays a critical role 
in the regulation of IRF-1 (45) in addition to its control at the 
transcriptional level (46). Under basal conditions, the rate of 
IRF-1 turnover is high (half-life 20–40 min), such that its steady-
state levels are maintained very low. Indeed, this transcription 
factor contains ubiquitination and degradation signals within its 
C-terminal region, which lead to its constitutive ubiquitination 
and degradation by the proteasome pathway (34–36). It is known 
that the IRF-1 levels rapidly increase in response to stimuli such 
as viral infection, DNA damage, or TLR stimulation (16, 47, 48) 
due not only to its transcriptional activation but also to changes in 
its posttranslational modification that greatly increase the protein 
stability.
To understand how SFKs modulate IRF-1 accumulation fol-
lowing TLRs engagement, we first measured the mRNA levels 
of IRF-1 in cells stimulated with the TLR7/8 agonist R848 and 
pretreated or not with the SKFs inhibitor, PP2. Because no dif-
ferences in IRF-1 transcript levels were found, we hypothesized 
that SFKs may be involved in the posttranslational regulation of 
IRF-1, in particular, in the ubiquitination of this transcription 
factor. Ubiquitin has a central role in many cellular functions, 
such as signal transduction, receptor downregulation, protein–
protein interaction, protein transport and degradation and 
gene transcription, which may be regulated by different types of 
ubiquination leading to different ubiquitin chains (49–51). The 
best characterized type of ubiquitin chain is formed by several 
ubiquitins linked through lysine 48 (K48) and is typically asso-
ciated with proteasome-mediated protein degradation (49, 51). 
Moreover, several proteins may be K63-linked ubiquitinated. 
This modification is known to be important in several cellular 
processes and, in particular, in the signal transduction of various 
activation pathways (49, 51). The activation and degradation of 
several IRFs, such as IRF5, IRF7 (39, 52, 53), and also IRF-1 (36, 
37), are regulated by both types of ubiquitination. Using hTLR7-
HEK293 cells transiently transfected with plasmids encoding 
ubiquitin mutants that form only K63 or K48-linked chains, we 
found that activation of SFKs results in an increase in K63-linked 
ubiquitination of IRF-1, which is reversed by kinase inhibition 
following PP2 treatment. On the contrary, the levels of K48-linked 
ubiquitinated IRF-1 were found to be increased by PP2 treat-
ment. These results suggest that, upon TLR7 engagement, IRF-1 
preferentially undergoes K63-linked ubiquitination and that 
this modification rescues it from degradation. Hence, consistent 
with our current understanding of IRF-1 regulation, the protein 
levels of IRF-1 are controlled posttranslationally by K48-linked 
ubiquitination and proteasomal degradation (36). Once SFKs are 
activated by TLR7/8, they trigger an increase in K63-linked ubiq-
uitination of IRF-1, resulting in the activation and accumulation 
of the transcription factor. Interestingly, several studies proved 
that both types of ubiquitination target the same residues in the 
DNA-binding domain of IRF-1. In particular Narayan et al. (54) 
suggested the possibility that K63-ubiquitination may counteract 
the constitutive K48-ubiquitination of IRF-1. We may, therefore, 
hypothesize that the two events compete, such that cells promote 
K48- or K63-linked ubiquitination depending on the external 
conditions.
It has been reported that IL-1-induced K63-linked ubiquitina-
tion of IRF-1 is catalyzed by the E3 ligase cIAP2, which in turn 
is activated through its ubiquitination by TRAF6. Moreover, 
these three proteins have been shown to interact with each 
other (43). TRAF6 is one of the major signal transducers of 
the TNF receptor family (42, 55) and has long been known to 
FigUre 6 | Schematic illustration of SFKs mechanism of action in interferon 
regulatory factor 1 (IRF-1) K63-Ubiquitination. (a) Activation of the TLR7/8 
pathway promotes the interaction between SFKs and TNFR-associated 
factor 6 (TRAF6) allowing the recruitment of both cIAP2 and IRF-1 by  
TRAF6 with the subsequent K63-ubiquitination and accumulation of IRF-1. 
(B) Preincubation with PP2 impairs the capacity of SFKs to interact with 
TRAF6 and the formation of the TRAF6-IRF1-cIAP2 complex, inhibiting 
K63-ubiquitination of IRF-1, which is, however, K48-ubiquitinylated and it is 
consequently degraded via proteasome.
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participate in TLR signaling, ubiquitinating itself and several 
proteins, including some IRFs (37, 39, 41). cIAP2, instead, not 
only regulates caspases and hence apoptosis, but has also been 
implicated in the modulation of inflammatory signaling (50, 56). 
We tested whether these proteins are also recruited to K63- 
linked ubiquitinated IRF-1 during TLR7/8 signaling and the role 
played by SFKs in regulating these interactions. We found that 
cIAP2 is able to bind TRAF6 and IRF-1, and that these interac-
tions are affected by PP2, suggesting that the activation of SFKs is 
an upstream essential step in this signaling cascade. While TRAF6 
also interacts with IRF-1, this event was found to be independ-
ent of SFKs activation. Finally, stimulation with TLR7/8 agonists 
leads to reciprocal modification of TRAF6 and SFKs in a SFKs 
activity-dependent manner. Reciprocal binding and modifica-
tion between TRAF6 and SFKs have been extensively described 
for different signaling pathways in multiple cells of the immune 
system, although the hierarchical position between these two 
molecules remains still unclear. In particular, it was reported 
that the interaction between TRAF6 and c-Src requires an active 
SFK kinase domain and that the polyproline sequence of TRAF6 
and the Src-homology 3 (SH3) domain of Src are required for 
the binding between these two proteins to take place (32, 46–49). 
Collectively, our results highlight a new mechanism, whereby 
TRAF6 acts as a linker between SFKs and cIAP2-dependent 
IRF-1 K63-linked ubiquitination.
In conclusion, our finding that SFKs are required for K63-
linked ubiquitination of IRF-1 and pro-inflammatory cytokine 
release demonstrates that SFKs activation is a key step in TLR7/8 
signaling. In particular, as depicted in Figure 6, the activation of 
SFKs appears necessary for their own interaction with TRAF6 
and for the recruitment of both cIAP2 and IRF-1 by TRAF6. 
These events lead to the formation of a complex that allows the 
interaction of cIAP2 and IRF-1 resulting in IRF-1 K63-linked 
ubiquitination and stabilization.
aUThOr cOnTriBUTiOns
LT, FC, and JV performed and analyzed the experiments; CB 
and UD designed research studies; LT, FC, CB, and UD wrote 
the paper. All authors reviewed the results and revised and 
approved the final version of the manuscript.
acKnOWleDgMenTs
We thank Dr. Jonathan Ashwell (NCI, NIH, Bethesda, MD, 
USA) for the plasmids encoding HA-tagged ubiquitins and 
Dr. Antonio Leonardi (University of Naples, Italy) for critical 
review of the manuscript. We also thank Marianna Taccone and 
Susanna Aprea for technical help in performing experiments with 
human primary monocytes.
FUnDing
This work was partially supported by a grant from MIUR 
(Medintech project CTN01_00177_962865) and European 
Commission through contract FP7-HEALTH-2011.1.4-4-280873 
(ADITEC). LT and FC were supported by a fellowship from 
Regione Toscana POR-FSE 2007-2013. JV was supported by 
the People Program (Marie Sklodowska-Curie Actions) of the 
European Union’s Seventh Framework Programme FP7/2007-
2013 under the REA Grant agreement 317057 HOMIN-ITN.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
http://www.frontiersin.org/articles/10.3389/fimmu.2018.00330/
full#supplementary-material.
reFerences
1. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking 
innate and acquired immunity. Nat Immunol (2001) 2(8):675–80. doi:10.1038/ 
90609 
2. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate 
receptors in infection and immunity. Immunity (2011) 34(5):637–50. 
doi:10.1016/j.immuni.2011.05.006 
3. Bauer S, Muller T, Hamm S. Pattern recognition by toll-like receptors. Adv Exp 
Med Biol (2009) 653:15–34. doi:10.1007/978-1-4419-0901-5_2 
4. Creagh EM, O’Neill LA. TLRs, NLRs and RLRs: a trinity of pathogen sensors 
that co-operate in innate immunity. Trends Immunol (2006) 27(8):352–7. 
doi:10.1016/j.it.2006.06.003 
5. Sasai M, Yamamoto M. Pathogen recognition receptors: ligands and signal-
ing pathways by toll-like receptors. Int Rev Immunol (2013) 32(2):116–33. 
doi:10.3109/08830185.2013.774391 
6. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. 
Int Immunol (2009) 21(4):317–37. doi:10.1093/intimm/dxp017 
7. Gay NJ, Gangloff M. Structure of toll-like receptors. Handb Exp Pharmacol 
(2008) 183:181–200. doi:10.1007/978-3-540-72167-3_9 
11
Tulli et al. SFKs Regulate IRF-1 K63-Linked Ubiquitination
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 330
8. Buonsanti C, D’Oro U. Chapter 5 – discovery of immune potentiators as 
vaccine adjuvants A2 – Schijns, Virgil E.J.C. 2nd ed. In: O’Hagan DT editor. 
Immunopotentiators in Modern Vaccines. Academic Press (2017). p. 85–104.
9. Bauer S, Pigisch S, Hangel D, Kaufmann A, Hamm S. Recognition of nucleic 
acid and nucleic acid analogs by toll-like receptors 7, 8 and 9. Immunobiology 
(2008) 213(3–4):315–28. doi:10.1016/j.imbio.2007.10.010 
10. Kawai T, Akira S. Antiviral signaling through pattern recognition receptors. 
J Biochem (2007) 141(2):137–45. doi:10.1093/jb/mvm032 
11. Buonsanti C, Balocchi C, Harfouche C, Corrente F, Galli Stampino L, 
Mancini F, et al. Novel adjuvant alum-TLR7 significantly potentiates immune 
response to glycoconjugate vaccines. Sci Rep (2016) 6:29063. doi:10.1038/
srep29063 
12. Wu TY, Singh M, Miller AT, De Gregorio E, Doro F, D’Oro U, et al. Rational 
design of small molecules as vaccine adjuvants. Sci Transl Med (2014) 6 
(263):263ra160. doi:10.1126/scitranslmed.3009980 
13. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. IRF-7 is 
the master regulator of type-I interferon-dependent immune responses. 
Nature (2005) 434:772. doi:10.1038/nature03464 
14. Li YF, Lee KG, Ou X, Lam KP. Bruton’s tyrosine kinase and protein kinase C 
micro are required for TLR7/9-induced IKKalpha and IRF-1 activation and 
interferon-beta production in conventional dendritic cells. PLoS One (2014) 
9(8):e105420. doi:10.1371/journal.pone.0105420 
15. Hoshino K, Sasaki I, Sugiyama T, Yano T, Yamazaki C, Yasui T, et al. Critical 
role of IkappaB Kinase alpha in TLR7/9-induced type I IFN production by 
conventional dendritic cells. J Immunol (2010) 184(7):3341–5. doi:10.4049/
jimmunol.0901648 
16. Kuka M, Baronio R, Valentini S, Monaci E, Muzzi A, Aprea S, et  al. Src 
kinases are required for a balanced production of IL-12/IL-23 in human 
dendritic cells activated by toll-like receptor agonists. PLoS One (2010) 5 
(7):e11491. doi:10.1371/journal.pone.0011491 
17. Chattopadhyay S, Sen GC. Tyrosine phosphorylation in toll-like receptor 
signaling. Cytokine Growth Factor Rev (2014) 25(5):533–41. doi:10.1016/j.
cytogfr.2014.06.002 
18. Gong P, Angelini DJ, Yang S, Xia G, Cross AS, Mann D, et  al. TLR4 
signaling is coupled to SRC family kinase activation, tyrosine phosphory- 
lation of zonula adherens proteins, and opening of the paracellular pathway 
in human lung microvascular endothelia. J Biol Chem (2008) 283(19): 
13437–49. doi:10.1074/jbc.M707986200 
19. Johnson P, Cross JL. Tyrosine phosphorylation in immune cells: direct 
and indirect effects on toll-like receptor-induced proinflammatory cyto-
kine production. Crit Rev Immunol (2009) 29(4):347–67. doi:10.1615/
CritRevImmunol.v29.i4.50 
20. Nguyen TT, Johnsen IB, Knetter CF, Drablos F, Fitzgerald KA, Lien E, et al. 
Differential gene expression downstream of toll-like receptors (TLRs): role 
of c-Src and activating transcription factor 3 (ATF3). J Biol Chem (2010) 
285(22):17011–9. doi:10.1074/jbc.M109.068817 
21. Napolitani G, Bortoletto N, Racioppi L, Lanzavecchia A, D’Oro U. Activation 
of src-family tyrosine kinases by LPS regulates cytokine production in 
dendritic cells by controlling AP-1 formation. Eur J Immunol (2003) 33(10): 
2832–41. doi:10.1002/eji.200324073 
22. Page TH, Smolinska M, Gillespie J, Urbaniak AM, Foxwell BM. Tyrosine 
kinases and inflammatory signalling. Curr Mol Med (2009) 9(1):69–85. 
doi:10.2174/156652409787314507 
23. Smolinska MJ, Page TH, Urbaniak AM, Mutch BE, Horwood NJ. Hck tyro- 
sine kinase regulates TLR4-induced TNF and IL-6 production via AP-1. 
J Immunol (2011) 187(11):6043–51. doi:10.4049/jimmunol.1100967 
24. Toubiana J, Rossi AL, Belaidouni N, Grimaldi D, Pene F, Chafey P, et  al. 
Src-family-tyrosine kinase Lyn is critical for TLR2-mediated NF-kappaB 
activation through the PI 3-kinase signaling pathway. Innate Immun (2015) 
21(7):685–97. doi:10.1177/1753425915586075 
25. Roskoski R Jr. Src kinase regulation by phosphorylation and dephosphor-
ylation. Biochem Biophys Res Commun (2005) 331(1):1–14. doi:10.1016/j.
bbrc.2005.08.055 
26. Xu W, Harrison SC, Eck MJ. Three-dimensional structure of the tyrosine 
kinase c-Src. Nature (1997) 385(6617):595–602. doi:10.1038/385595a0 
27. Harada H, Fujita T, Miyamoto M, Kimura Y, Maruyama M, Furia A, et  al. 
Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind 
to the same regulatory elements of IFN and IFN-inducible genes. Cell (1989) 
58(4):729–39. doi:10.1016/0092-8674(89)90107-4 
28. Ikushima H, Negishi H, Taniguchi T. The IRF family transcription factors 
at the interface of innate and adaptive immune responses. Cold Spring Harb 
Symp Quant Biol (2013) 78:105–16. doi:10.1101/sqb.2013.78.020321 
29. Escalante CR, Yie J, Thanos D, Aggarwal AK. Structure of IRF-1 with 
bound DNA reveals determinants of interferon regulation. Nature (1998) 
391(6662):103–6. doi:10.1038/34224 
30. Dror N, Alter-Koltunoff M, Azriel A, Amariglio N, Jacob-Hirsch J, 
Zeligson S, et al. Identification of IRF-8 and IRF-1 target genes in activated 
macrophages. Mol Immunol (2007) 44(4):338–46. doi:10.1016/j.molimm. 
2006.02.026 
31. Negishi H, Fujita Y, Yanai H, Sakaguchi S, Ouyang X, Shinohara M, et  al. 
Evidence for licensing of IFN-gamma-induced IFN regulatory factor 1 
transcription factor by MyD88 in toll-like receptor-dependent gene induction 
program. Proc Natl Acad Sci U S A (2006) 103(41):15136–41. doi:10.1073/
pnas.0607181103 
32. Dou L, Liang HF, Geller DA, Chen YF, Chen XP. The regulation role of inter-
feron regulatory factor-1 gene and clinical relevance. Hum Immunol (2014) 
75(11):1110–4. doi:10.1016/j.humimm.2014.09.015 
33. Kim EJ, Park JS, Um SJ. Ubc9-mediated sumoylation leads to transcriptional 
repression of IRF-1. Biochem Biophys Res Commun (2008) 377(3):952–6. 
doi:10.1016/j.bbrc.2008.10.092 
34. Luu K, Greenhill CJ, Majoros A, Decker T, Jenkins BJ, Mansell A. STAT1 
plays a role in TLR signal transduction and inflammatory responses. 
Immunol Cell Biol (2014) 92(9):761–9. doi:10.1038/icb.2014.51 
35. Nakagawa K, Yokosawa H. PIAS3 induces SUMO-1 modification and tran-
scriptional repression of IRF-1. FEBS Lett (2002) 530(1–3):204–8. doi:10.1016/
S0014-5793(02)03486-5 
36. Nakagawa K, Yokosawa H. Degradation of transcription factor IRF-1 by the 
ubiquitin-proteasome pathway. The C-terminal region governs the protein 
stability. Eur J Biochem (2000) 267(6):1680–6. doi:10.1046/j.1432-1327.2000. 
01163.x 
37. Harikumar KB, Yester JW, Surace MJ, Oyeniran C, Price MM, Huang WC, 
et al. K63-linked polyubiquitination of transcription factor IRF1 is essential 
for IL-1-induced production of chemokines CXCL10 and CCL5. Nat Im- 
munol (2014) 15(3):231–8. doi:10.1038/ni.2810 
38. Capitani N, Patrussi L, Trentin L, Lucherini OM, Cannizzaro E, Migliaccio E, 
et  al. S1P1 expression is controlled by the pro-oxidant activity of p66Shc 
and is impaired in B-CLL patients with unfavorable prognosis. Blood (2012) 
120(22):4391–9. doi:10.1182/blood-2012-04-425959 
39. Konno H, Yamamoto T, Yamazaki K, Gohda J, Akiyama T, Semba K, et al. 
TRAF6 establishes innate immune responses by activating NF-kappaB and 
IRF7 upon sensing cytosolic viral RNA and DNA. PLoS One (2009) 4(5):e5674. 
doi:10.1371/journal.pone.0005674 
40. Sasai M, Tatematsu M, Oshiumi H, Funami K, Matsumoto M, Hatakeyama 
S, et  al. Direct binding of TRAF2 and TRAF6 to TICAM-1/TRIF adaptor 
participates in activation of the Toll-like receptor 3/4 pathway. Mol Immunol 
(2010) 47(6):1283–91. doi:10.1016/j.molimm.2009.12.002 
41. Ning S, Campos AD, Darnay BG, Bentz GL, Pagano JS. TRAF6 and the three 
C-terminal lysine sites on IRF7 are required for its ubiquitination-mediated 
activation by the tumor necrosis factor receptor family member latent 
membrane protein 1. Mol Cell Biol (2008) 28(20):6536–46. doi:10.1128/
MCB.00785-08 
42. Xie P. TRAF molecules in cell signaling and in human diseases. J Mol Signal 
(2013) 8(1):7. doi:10.1186/1750-2187-8-7 
43. Liu A, Gong P, Hyun SW, Wang KZ, Cates EA, Perkins D, et  al. TRAF6 
protein couples toll-like receptor 4 signaling to Src family kinase activation 
and opening of paracellular pathway in human lung microvascular endo- 
thelia. J Biol Chem (2012) 287(20):16132–45. doi:10.1074/jbc.M111.310102 
44. Kondo T, Kawai T, Akira S. Dissecting negative regulation of toll-like recep-
tor signaling. Trends Immunol (2012) 33(9):449–58. doi:10.1016/j.it.2012. 
05.002 
45. Watanabe N, Sakakibara J, Hovanessian AG, Taniguchi T, Fujita T. Activation 
of IFN-β element by IRF-1 requires a post-translational event in addition 
to IRF-1 synthesis. Nucleic Acids Res (1991) 19(16):4421–8. doi:10.1093/
nar/19.16.4421 
46. Sims SH, Cha Y, Romine MF, Gao PQ, Gottlieb K, Deisseroth AB. A novel 
interferon-inducible domain: structural and functional analysis of the 
human interferon regulatory factor 1 gene promoter. Mol Cell Biol (1993) 
13(1):690–702. doi:10.1128/MCB.13.1.690 
12
Tulli et al. SFKs Regulate IRF-1 K63-Linked Ubiquitination
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 330
47. Ren G, Cui K, Zhang Z, Zhao K. Division of labor between IRF1 and IRF2 
in regulating different stages of transcriptional activation in cellular anti- 
viral activities. Cell Biosci (2015) 5:17. doi:10.1186/s13578-015-0007-0 
48. Pitha PM, Au WC, Lowther W, Juang YT, Schafer SL, Burysek L, et  al. 
Role of the interferon regulatory factors (IRFs) in virus-mediated signaling 
and regulation of cell growth. Biochimie (1998) 80(8–9):651–8. doi:10.1016/
S0300-9084(99)80018-2 
49. Rieser E, Cordier SM, Walczak H. Linear ubiquitination: a newly discov-
ered regulator of cell signalling. Trends Biochem Sci (2013) 38(2):94–102. 
doi:10.1016/j.tibs.2012.11.007 
50. Feltham R, Khan N, Silke J. IAPS and ubiquitylation. IUBMB Life (2012) 
64(5):411–8. doi:10.1002/iub.565 
51. Liu YC. Ubiquitin ligases and the immune response. Annu Rev Immunol 
(2004) 22:81–127. doi:10.1146/annurev.immunol.22.012703.104813 
52. Balkhi MY, Fitzgerald KA, Pitha PM. IKKalpha negatively regulates IRF-5 
function in a MyD88-TRAF6 pathway. Cell Signal (2010) 22(1):117–27. 
doi:10.1016/j.cellsig.2009.09.021 
53. Balkhi MY, Fitzgerald KA, Pitha PM. Functional regulation of MyD88-
activated interferon regulatory factor 5 by K63-linked polyubiquitination. 
Mol Cell Biol (2008) 28(24):7296–308. doi:10.1128/MCB.00662-08 
54. Narayan V, Pion E, Landre V, Muller P, Ball KL. Docking-dependent ubiq-
uitination of the interferon regulatory factor-1 tumor suppressor protein 
by the ubiquitin ligase CHIP. J Biol Chem (2011) 286(1):607–19. doi:10.1074/
jbc.M110.153122 
55. Inoue J, Gohda J, Akiyama T. Characteristics and biological functions of 
TRAF6. Adv Exp Med Biol (2007) 597:72–9. doi:10.1007/978-0-387-70630-6_6 
56. Budhidarmo R, Day CL. IAPs: modular regulators of cell signalling. Semin Cell 
Dev Biol (2015) 39:80–90. doi:10.1016/j.semcdb.2014.12.002 
Conflict of Interest Statement: JV is a former employee of the GSK group of com-
panies. UD is an employee of the GSK group of companies and reports ownership 
of restricted GSK shares. LT was a recipient of a scholarship from GSK Vaccines 
S.r.l on a grant from MIUR (Medintech training project CTN01_00177_962865). 
All other authors declare that they have no conflicts of interest with the contents 
of this article.
Copyright © 2018 Tulli, Cattaneo, Vinot, Baldari and D’Oro. This is an open-access 
article distributed under the terms of the Creative Commons Attribution License 
(CC BY). The use, distribution or reproduction in other forums is permitted, 
provided the original author(s) and the copyright owner are credited and that the 
original publication in this journal is cited, in accordance with accepted academic 
practice. No use, distribution or reproduction is permitted which does not comply 
with these terms.
